Nxera Pharma Co., Ltd.
IND Acceptance for NBI-1117567 Phase 2 Trial Targeting Cognitive Impairment in Alzheimer’s Disease by Partner Neuroklin
In light of FDA IND acceptance for NBI-1117567, a milestone of USD 10 million will be received from Neuroklin. Nexera Pharma retains development and commercialization rights for M1 receptor agonists in Japan. Revenue is expected to be recorded in the third quarter of fiscal year 2026.
Key Figures
- Milestone receipt amount: 10 百万米ドル
- Timing of revenue recognition: FY2026 Q3
- Development and commercialization rights: Japan—holding development and commercialization rights for muscarinic M1 receptor agonists
AI要約
Section Heading
Acquisition of milestones based on IND acceptance for NBI-1117567 by partner Neuroklin and the financial impact of this matter. Description of the development status of the muscarinic receptor agonist class under the NxWave platform and the handling of development and commercialization rights in the Japanese market.
Section 2 Heading
Commentary on future pipeline progress and market opportunities, Japan and global development cost burden structure, and long-term monetization outlook. It notes that the short-term financial impact of IND acceptance is already incorporated in FY2026 Q3 revenue.
Nexera Pharma Co., Ltd.
Company overview · Stock price · Financial data · All IR
